Orthofix raises 2026 net sales outlook to $845 mln-$855 mln from $838 mln-$848 mln
Company lifts 2026 adjusted EBITDA guidance to $95 mln-$98 mln from $90 mln-$93 mln
Overview
U.S. medical device maker's Q2 sales rose 4% and slightly beat analyst expectations
Adjusted EBITDA for Q2 missed analyst estimates
Company raised full-year 2026 sales and adjusted EBITDA guidance
Result Drivers
Segment growth - Double-digit constant currency growth in Global Spine Fixation and Global Limb Reconstruction, driven by strong international performance and demand across key platforms
Biologics momentum - Biologics stabilized and began to regain momentum, supported by focused commercial execution
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Orthofix Medical Inc. is $16.00, about 31.1% above its August 4 closing price of $12.20
OFIX•
